Verana Health Leads First-of-its-Kind Study Demonstrating Promise of Real-World Data in Ophthalmic Clinical Development
Retrieved on:
Wednesday, May 5, 2021
Data management, Health, Technology, Software, Clinical trials, General Health, Clinical research, Health sciences, Health, Medical research, Design of experiments, Evidence, Health informatics, Real world data, Clinical trial, Randomized controlled trial, Ophthalmology, Verana Health, the American Academy of Ophthalmology, VERANA HEALTH, THE AMERICAN ACADEMY OF OPHTHALMOLOGY
In a first-of-its kind study , Verana Health demonstrated that it was able to successfully use real world data (RWD) to replicate primary outcome measures of two large-scale randomized controlled trials (RCTs) in ophthalmology\xe2\x80\x94the VIEW 1 and VIEW 2 (VIEW 1/2) pivotal trials.
Key Points:
- In a first-of-its kind study , Verana Health demonstrated that it was able to successfully use real world data (RWD) to replicate primary outcome measures of two large-scale randomized controlled trials (RCTs) in ophthalmology\xe2\x80\x94the VIEW 1 and VIEW 2 (VIEW 1/2) pivotal trials.
- The groundbreaking replication of the VIEW 1/2 clinical trials outcomes data shows the potential value real-world data can bring in helping to accelerate clinical trials," said David W. Parke II, MD, CEO of the American Academy of Ophthalmology.
- "The research demonstrating the viability of linking imaging metadata to IRIS Registry encounters is also encouraging.
- Currently, the IRIS Registry does not contain images, yet they are a critical component of the daily practice of ophthalmology.